Deep Vein Thrombosis (DVT) Pipeline

DelveInsight’s, “Deep Vein Thrombosis (DVT) - Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Deep Vein Thrombosis (DVT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Deep Vein Thrombosis (DVT): Understanding

Deep Vein Thrombosis (DVT): Overview

Deep vein thrombosis (DVT) is a common venous thromboembolic (VTE) disorder characterized by the formation of blood clots within the deep veins, most often in the lower limbs but also occurring in the arms, mesenteric, or cerebral veins. Clots typically originate in the deep calf veins and may extend proximally, with site involvement distributed as distal veins (40%), popliteal (16%), femoral (20%), common femoral (20%), and iliac veins (4%). With an annual incidence of 1.6 per 1000 individuals, DVT represents a significant medical concern, ranking as the third leading cause of cardiovascular mortality after myocardial infarction and stroke. Beyond its role as the primary source of pulmonary embolism, DVT contributes to considerable morbidity through recurrent thrombosis and post-thrombotic syndrome, underscoring the critical importance of early diagnosis and timely intervention.

Risk factors for deep vein thrombosis (DVT) include reduced blood flow from immobility, surgery, anesthesia, stroke, or prolonged travel; increased venous pressure due to pregnancy, tumors, or venous anomalies; and mechanical injury from trauma, prior DVT, or venous catheters. Conditions that raise blood viscosity, such as polycythemia and dehydration, along with genetic predispositions (factor V Leiden mutation, protein C/S or antithrombin III deficiencies) and acquired disorders (cancer, sepsis, autoimmune disease, heart failure, diabetes, smoking also contribute to risk. Constitutional factors like obesity, advanced age, pregnancy, and critical illness further predispose individuals, with obesity being particularly significant due to hypercoagulability and impaired venous flow. Risks are categorized as transient (e.g., surgery, hospitalization, hormone therapy, pregnancy), persistent (e.g., cancer, lupus, inflammatory bowel disease), or unprovoked, with recent evidence suggesting lipid metabolism may also influence susceptibility.

Thrombosis serves as a protective mechanism to prevent blood loss and seal injured vessels, while fibrinolysis acts to counterbalance or stabilize clot formation. Venous thrombosis is typically multifactorial, with varying contributions from Virchow’s triad, all converging on early thrombus–endothelium interaction, which triggers cytokine release and leukocyte adhesion, thereby promoting clot development. The progression of thrombosis depends on the balance between coagulation and fibrinolytic pathways, with DVT most commonly arising in the lower limb below the knee, particularly at low-flow sites such as the soleal sinuses and behind venous valve pockets. Emerging evidence also suggests a potential link between DVT and atherosclerosis, as endothelial dysfunction underlying DVT may predispose patients to subsequent atherosclerotic disease.

The diagnosis of deep vein thrombosis (DVT) involves a combination of clinical assessment, laboratory testing, and imaging. Clinically, patients may present with asymmetrical limb swelling, warmth, or pain, and risk stratification is commonly performed using the Wells scoring system, which categorizes patients as “likely” or “unlikely” to have DVT and demonstrates moderate sensitivity and specificity. The D-dimer assay, which measures fibrin degradation products, is highly sensitive but nonspecific, making it useful for ruling out DVT in low-risk patients when combined with clinical scoring. Imaging, particularly ultrasound, is the first-line diagnostic tool owing to its safety, accessibility, and reliability in detecting proximal clots, although its sensitivity is lower for distal DVT. Other modalities such as contrast venography (the gold standard), CT venography, and MR venography may be employed in select cases, each with advantages and limitations related to accuracy, invasiveness, availability, and patient tolerance. Ultimately, integrating clinical scoring, D-dimer testing, and imaging ensures a more accurate and efficient diagnostic approach to DVT.

The treatment of deep vein thrombosis (DVT) focuses on preventing pulmonary embolism, reducing morbidity, and lowering the risk of post-thrombotic syndrome, with anticoagulation serving as the cornerstone of therapy. Current NICE guidelines recommend treating proximal DVT and cases associated with pulmonary embolism, while newer oral factor Xa inhibitors such as rivaroxaban, apixaban, dabigatran, edoxaban, and betrixaban are widely approved for prophylaxis. The typical treatment duration is 3–6 months, though recurrent DVT may require at least 12 months of therapy, and patients with cancer often need extended treatment. Inferior vena cava (IVC) filters, whether permanent or temporary, are generally discouraged as they do not improve survival and are reserved only for patients with contraindications to anticoagulation who are at high risk of bleeding.

 

"Deep Vein Thrombosis (DVT)- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Deep Vein Thrombosis (DVT) pipeline landscape is provided which includes the disease overview and Deep Vein Thrombosis (DVT) treatment guidelines. The assessment part of the report embraces, in depth Deep Vein Thrombosis (DVT) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Deep Vein Thrombosis (DVT) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Deep Vein Thrombosis (DVT) R&D. The therapies under development are focused on novel approaches to treat/improve Deep Vein Thrombosis (DVT).

 

Deep Vein Thrombosis (DVT) Emerging Drugs Chapters

This segment of the Deep Vein Thrombosis (DVT) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Deep Vein Thrombosis (DVT) Emerging Drugs

• Abelacimab: Novartis

Abelacimab is a fully human monoclonal antibody that selectively inhibits Factor XI, mimicking natural deficiency and protecting against thromboembolic disease. It is not metabolized via CYP450 or P-glycoprotein, minimizing drug–drug interactions, and requires no dose adjustment for age or organ function, making it safe with antiplatelet agents. For atrial fibrillation, it is administered as a one-time IV infusion for rapid effect, followed by monthly subcutaneous injections via autoinjector. The FDA granted Fast Track Designation in 2022 for cancer-associated thrombosis and for stroke prevention in atrial fibrillation. Currently, the drug is in Phase III stage of its development for the treatment of Deep venous thrombosis.

Further product details are provided in the report……..

 

Deep Vein Thrombosis (DVT): Therapeutic Assessment

This segment of the report provides insights about the different Deep Vein Thrombosis (DVT) drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Deep Vein Thrombosis (DVT)

• There are approx. 2+ key companies which are developing the therapies for Deep Vein Thrombosis (DVT). The companies which have their Deep Vein Thrombosis (DVT) drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

 

Phases

DelveInsight’s report covers around 2+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Deep Vein Thrombosis (DVT) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Deep Vein Thrombosis (DVT): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Deep Vein Thrombosis (DVT) therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Deep Vein Thrombosis (DVT) drugs.

 

Deep Vein Thrombosis (DVT) Report Insights

• Deep Vein Thrombosis (DVT) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Deep Vein Thrombosis (DVT) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Deep Vein Thrombosis (DVT) drugs?
• How many Deep Vein Thrombosis (DVT) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Deep Vein Thrombosis (DVT)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Deep Vein Thrombosis (DVT) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Deep Vein Thrombosis (DVT) and their status?
• What are the key designations that have been granted to the emerging drugs?